Portal de Periódicos da CAPES

Treatment-related myelodysplasia/AML in a patient with a history of breast cancer and an oligodendroglioma treated with temozolomide: Case study and review of the literature1

2006; Oxford University Press; Volume: 8; Issue: 3 Linguagem: Inglês

10.1215/15228517-2006-003

1523-5866

Vanita Noronha, Nancy Berliner, Karen K. Ballen, Jill Lacy, Jean Kracher, Joachim M. Baehring, John W. Henson,

Acute Myeloid Leukemia Research

The emergence of temozolomide as an effective alkylating agent with little acute toxicity or cumulative myelosuppression has led to protracted courses of chemotherapy for many patients with gliomas. Secondary, or treatment-related, myelodysplasia (t-MDS) and acute myelogenous leukemia (t-AML) are life-threatening complications of alkylating chemotherapy and have been reported in patients with primary brain tumors. We describe a case of temozolomide-related t-MDS/AML and discuss the clinical features of this condition. Administration of an alkylating agent in patient populations with long median survivals must be undertaken with an understanding of the potential for this treatment complication.